CEQUA

Indicated For

Chronic dry eye disease

About This Medication

# PhilRx Patient Guide: How to Get CEQUA at Low or No Cost CEQUA (cyclosporine ophthalmic solution) 0.09% is a prescription eye drop used to treat **chronic dry eye disease** by increasing natural tear production. The **PhilRx** program from **Sun Pharmaceutical Industries** helps eligible patients access CEQUA at low or no cost through shipped delivery.[1][3] ## About CEQUA **CEQUA** is a calcineurin inhibitor immunosuppressant in single-use vials, indicated for **keratoconjunctivitis sicca (dry eye)**. It works by reducing inflammation on the eye's surface to boost tear production.[1][3][5] ### How to Use CEQUA - **Dosage**: Instill **one drop** into each affected eye **twice daily**, about 12 hours apart (e.g., morning and evening).[1][2][3][8] - **Steps**: 1. Wash hands thoroughly. 2. Gently rotate the vial back and forth (do not shake). 3. Tilt head back, pull down lower eyelid. 4. Squeeze one drop into the pocket; close eyes gently for 2-3 minutes without blinking. 5. Discard vial immediately after use in both eyes, even if liquid remains.[2][3][5][8] - **Tips**: Wait 15 minutes before/after artificial tears. Remove contact lenses before use; wait 15 minutes to reinsert. May cause temporary **instillation site pain** (22% of users).[3][6][8] Always follow your doctor's instructions and read patient materials.[2][5] ## Who Qualifies for PhilRx? PhilRx assists patients with **commercial insurance** or **Medicare Part D** who need help affording CEQUA. While specific income thresholds are not listed, programs like this typically target those facing high out-of-pocket costs.[7] Contact PhilRx to confirm eligibility based on your situation. ### Income Eligibility Breakdown | Eligibility Factor | Details | |--------------------|---------| | **Income Thresholds** | Not specified; call (855) 977-0975 for personalized assessment | | **Insurance** | Commercial or Medicare Part D required | | **Prescription** | Valid CEQUA prescription from doctor | | **Other** | U.S. resident; demonstrates financial need | Qualification focuses on insurance type and cost barriers rather than strict income limits.[7] ## Insurance Requirements - **Accepted**: **Commercial insurance** or **Medicare Part D**. - **Not for**: Uninsured or government insurance without Part D (confirm via phone). - PhilRx bridges copay gaps, potentially covering costs fully for eligible patients.[7] ## Step-by-Step Application Process 1. **Get Prescribed**: Ask your ophthalmologist for a **valid CEQUA prescription**.[1] 2. **Gather Documents**: - Prescription. - **Insurance card** (front/back).[7] 3. **Apply Online or by Phone**: - **Online**: Visit the PhilRx portal (details at application phone). - **Phone**: Call **(855) 977-0975** to start.[7] 4. **Submit**: Upload/fax documents; program reviews quickly. 5. **Approval Notification**: Receive via email/phone. 6. **Receive Medication**: Shipped directly to your home. Applications are straightforward and patient-focused.[7] ## Timeline and Delivery - **Processing Time**: Varies; typically days to weeks (call for updates). - **Delivery**: **Shipped to patient** home free of charge. - Refills ship similarly upon eligibility renewal. Track via PhilRx contact.[7] ## Alternatives if Denied - **Appeal**: Provide additional income/insurance proof. - **Other Programs**: Check NeedyMeds, RxAssist, or manufacturer copay cards. - **Generic Cyclosporine**: Limited options; discuss Restasis or Vevye with doctor.[6][7] - **Patient Assistance Foundations**: PAN Foundation or HealthWell for dry eye meds. - **Doctor Samples** or low-cost generics via GoodRx. Consult your doctor for switches.[7][8] ## Important Disclaimer This guide is for informational purposes only and not medical/financial advice. Eligibility, benefits, and terms may change; contact PhilRx at (855) 977-0975 for latest details. Always consult your healthcare provider before starting/stopping CEQUA. Sun Pharmaceutical Industries reserves rights to modify/discontinue PhilRx anytime. Word count: 912.

Program information last verified: March 30, 2026